BioSpace News Archive

MedAlliance has announced completion of patient enrolment in the ISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis

Braid Health has secured FDA clearance for its AI-powered diagnostic collaboration software, improving diagnostic access and reducing costs for large healthcare systems, urgent care clinics, and retail clinics.

-- Becker’s Spine listed Centinel Spine as the top Orthopedic Solution Company in 2020 -- Becker’s Spine referenced MedTech Outlook as the source behind the recognition of innovators at the forefront of orthopedic technologies -- Centinel Spine has been named to the Top 10 list of innovators in the orthopedic market for the second year in a row

City of Hope has initiated a phase 1 clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.

Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (“CMC”).

NeuroRx, Inc., and Relief AG (SIX: RLF, OTCQB: RLFTF), announce that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100TM in the United States.

Jupiter Wellness, Inc.announced today they are initiating a clinical study of its CaniSun™ sunscreen lotion for the treatment of actinic keratosis (AK), the most common precancer that forms on the skin as a result of exposure to ultraviolet (UV) rays.

Annual program honors individuals for their outstanding efforts in making a difference for patients living with myeloproliferative neoplasms (MPNs)

Company to present 11 abstracts at RSNA 2020, consisted of studies that feature its AI solution for chest x-ray and mammography analysis

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced the publication of results from a phase 2a clinical trial of emixustat hydrochloride (emixustat) in patients with macular atrophy (MA) secondary to Stargardt disease (STGD) in the medical journal British Journal of Ophthalmology. The published arti